Patents by Inventor Cynthia Beaudet

Cynthia Beaudet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ROS KINASE IN LUNG CANCER
    Publication number: 20210349095
    Abstract: The invention provides the identification of the presence of polypeptides with ROS kinase activity in mammalian lung cancer. In some embodiments, the polypeptide with ROS kinase activity is the result of a fusion between a ROS-encoding polynucleotide and a polynucleotide encoding a second (non-ROS) polypeptide. Three different fusion partners of ROS are described, namely proteins encoded by the FIG gene, the SLC34A2 gene, and the CD74 gene. The invention enables new methods for determining the presence of a polypeptide with ROS kinase activity in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer (e.g., an lung cancer).
    Type: Application
    Filed: July 16, 2021
    Publication date: November 11, 2021
    Applicant: CELL SIGNALING TECHNOLOGY, INC.
    Inventors: Victoria McGuinness Rimkunas, Herbert Haack, Ting-Lei Gu, Ailan Guo, Anthony Paul Possemato, Katherine Eleanor Crosby, Meghan Ann Tucker, Cynthia Beaudet
  • ROS kinase in lung cancer
    Patent number: 11099188
    Abstract: The invention provides the identification of the presence of polypeptides with ROS kinase activity in mammalian lung cancer. In some embodiments, the polypeptide with ROS kinase activity is the result of a fusion between a ROS-encoding polynucleotide and a polynucleotide encoding a second (non-ROS) polypeptide. Three different fusion partners of ROS are described, namely proteins encoded by the FIG gene, the SLC34A2 gene, and the CD74 gene. The invention enables new methods for determining the presence of a polypeptide with ROS kinase activity in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer (e.g., an lung cancer).
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 24, 2021
    Assignee: CELL SIGNALING TECHNOLOGY, INC.
    Inventors: Victoria McGuinness Rimkunas, Herbert Haack, Ting-Lei Gu, Ailan Guo, Anthony Paul Possemato, Katherine Eleanor Crosby, Meghan Ann Tucker, Cynthia Beaudet